Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $275,280.00 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 31,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was bought at an average cost of $8.88 per share, with a total value of $275,280.00. Following the acquisition, the director owned 16,794,043 shares of the company’s stock, valued at approximately $149,131,101.84. The trade was a 0.18% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Trading Up 1.0%

Artiva Biotherapeutics stock opened at $9.80 on Thursday. The company has a 50-day moving average price of $9.22 and a 200 day moving average price of $6.72. Artiva Biotherapeutics, Inc. has a 12-month low of $1.53 and a 12-month high of $14.53. The stock has a market cap of $242.26 million, a P/E ratio of -2.77 and a beta of 2.17.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ARTV. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. HC Wainwright upped their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Finally, Needham & Company LLC restated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares during the period. Prelude Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at $41,000. Dimensional Fund Advisors LP acquired a new position in Artiva Biotherapeutics during the 1st quarter worth about $131,000. OMERS ADMINISTRATION Corp acquired a new position in Artiva Biotherapeutics during the 4th quarter worth about $91,000. Finally, Sanctuary Advisors LLC acquired a new position in Artiva Biotherapeutics in the 1st quarter valued at about $139,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.